Adverse effects ( · adult participants (> 16 years of age) undergoing intestinal resection due to Crohn's disease
It is very uncertain whether initiation of prophylactic therapy guided by colonoscopy changes adverse effects ( compared with initiation of prophylactic therapy immediately after surgery (very low certainty).
1 finding from 1 review
Clinical recurrence (until week 102) · adult participants (> 16 years of age) undergoing intestinal resection due to Crohn's disease
It is very uncertain whether initiation of prophylactic therapy guided by colonoscopy changes clinical recurrence (until week 102) compared with initiation of prophylactic therapy immediately after surgery (very low certainty).
1 finding from 1 review
Endoscopic recurrence · adult participants (> 16 years of age) undergoing intestinal resection due to Crohn's disease
It is very uncertain whether initiation of prophylactic therapy guided by colonoscopy changes endoscopic recurrence (at week 102) compared with initiation of prophylactic therapy immediately after surgery (very low certainty).
1 finding from 1 review
Surgical recurrence ( · adult participants (> 16 years of age) undergoing intestinal resection due to Crohn's disease
It is very uncertain whether initiation of prophylactic therapy guided by colonoscopy changes surgical recurrence ( compared with initiation of prophylactic therapy immediately after surgery (very low certainty).
1 finding from 1 review
RR 0.79 [0.38, 1.62]
133 participants
Very low
Remission
Family therapy may leads to higher remission post‐intervention compared with standard care/treatment (low certainty).
2 findings from 1 review
Mortality at long‐term
1 finding from 1 review
Remission
It is very uncertain whether family therapy changes remission post‐intervention compared with psychological interventions (very low certainty).
2 findings from 1 review
All‐cause mortality ‐ long‐term outcome
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Remission
It is very uncertain whether family therapy changes remission at long‐term compared with educational interventions (very low certainty).
1 finding from 1 review
Overall survival ( · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) showed no clear difference in overall survival ( compared with surgery followed by chemotherapy (PDS) (high certainty).
1 finding from 1 review
Progression‐free survival · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) showed no clear difference in progression‐free survival ( compared with surgery followed by chemotherapy (PDS) (moderate certainty).
1 finding from 1 review
Surgically‐related severe adverse effects (grade 3+) ‐ stoma formation (within 30 days of surgery) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ stoma… compared with surgery followed by chemotherapy (PDS) (moderate certainty).
1 finding from 1 review
Surgically‐related severe adverse effects (grade 3+) ‐ bowel resection (within 30 days of surgery) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ bowel… compared with surgery followed by chemotherapy (PDS) (moderate certainty).
1 finding from 1 review
Surgically‐related severe adverse effects (grade 3+) ‐ postoperative G3+ events (within 30 days of surgery) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ postoperative… compared with surgery followed by chemotherapy (PDS) (moderate certainty).
1 finding from 1 review
Surgically‐related postoperative mortality (28 days to 6 months of surgery4) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) leads to lower surgically‐related postoperative mortality (28 days to 6 months of… compared with surgery followed by chemotherapy (PDS) (high certainty).
1 finding from 1 review
EORTC QLQ‐C30 QoL at 6 months ‐ global health · women with advanced ovarian epithelial cancer
1 finding from 1 review
Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins
1 finding from 1 review
Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins
Sclerotherapy (STS) probably leads to higher adverse events ‐ hyperpigmentation ( compared with sclerotherapy (any sclerosant) (moderate certainty).
1 finding from 1 review
Adverse events ‐ matting ( · people with telangiectasias and reticular veins
Sclerotherapy (STS) probably leads to higher adverse events ‐ matting ( compared with sclerotherapy (any sclerosant) (moderate certainty).
1 finding from 1 review
Pain ( · people with telangiectasias and reticular veins
Sclerotherapy (STS) showed no clear difference in pain ( compared with sclerotherapy (any sclerosant) (moderate certainty).
1 finding from 1 review